News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under
View HTML
Toggle Summary Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program
The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website
View HTML
Toggle Summary Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
RNA Franchise Advances -Reported EXONDYS 51® (eteplirsen) net sales of $84.4M for the quarter and full-year net sales of $301.0M , in line with guidance- -Filed NDA for golodirsen with priority review, PDUFA August 19 th - Gene Therapy Engine Advances -Presented positive preliminary clinical data
View HTML
Toggle Summary Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
-- In two-month post-treatment muscle biopsies, clinical trial participants showed a mean of 51% beta-sarcoglycan (beta-SG) positive fibers, as measured by immunohistochemistry (IHC), substantially exceeding the pre-defined 20% measure for success -- -- Robust expression was also quantified by
View HTML
Toggle Summary Sarepta Exercises Option to Acquire Myonexus Therapeutics
-- Exercise Fee is $165 Million -- -- Sarepta to Acquire Myonexus’ Portfolio of Five Gene Therapy Candidates to Treat Distinct Forms of Limb-Girdle Muscular Dystrophy (LGMD) -- CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML
Toggle Summary Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
CAMBRIDGE, Mass. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that commencing at 8:00 a.m. Eastern Time (ET) on Wednesday February 27, 2019 , it will host a webcast and conference call to announce
View HTML
Toggle Summary Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
-- Trial to assess efficacy on neurodevelopmental status of MPS IIIA patients -- CAMBRIDGE, Mass. and PARIS , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, and
View HTML
Toggle Summary Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
-- FDA Grants Priority Review Status -- -- Regulatory Action Date is August 19 , 2019 -- -- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne -- CAMBRIDGE, Mass. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics,
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under
View HTML
Toggle Summary Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy
-- Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs -- -- Aldevron, a leading producer
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.